| 摘要: |
| ［摘要］ 目的 探讨载药微球经肝动脉化疗栓塞术(DEB-TACE)联合系统性抗肿瘤方案治疗不可切除原发性肝癌（PHC）的临床疗效及安全性。方法 回顾性分析2021年1月至2022年12月于南充市中心医院接受DEB-TACE治疗的99例不可切除PHC患者的临床资料。根据接受联合系统性抗肿瘤方案治疗情况将其分为对照组（单纯接受DEB-TACE治疗，44例）、联合A组（接受DEB-TACE联合靶向治疗，24例）、联合B组（接受DEB-TACE联合免疫治疗，16例）和联合C组（接受DEB-TACE联合免疫+靶向治疗，15例）。比较四组的临床疗效、生存预后及不良反应发生情况。结果 联合A组、联合B组及联合C组的客观缓解率（ORR）、疾病控制率(DCR)均高于对照组，总体生存（OS）时间及无疾病进展（PFS）时间均长于对照组，差异有统计学意义（P<0.05）。联合A组、联合B组及联合C组间ORR、DCR、OS时间、PFS时间比较差异无统计学意义（P>0.05）。与对照组相比，联合A组、联合B组及联合C组均出现与治疗药物相关的特征性不良反应，经对症处理后，相关不良反应症状均减轻或消失，不良反应等级均未超过Ⅲ级。结论 DEB-TACE联合系统性抗肿瘤方案治疗中晚期PHC临床疗效及安全性良好。 |
| 关键词: 原发性肝癌 载药微球经肝动脉化疗栓塞术 免疫治疗 靶向治疗 |
| DOI：10.3969/j.issn.1674-3806.2023.11.10 |
| 分类号:R 735.7 |
| 基金项目:四川省医学会医学科研课题项目（编号：S21085） |
|
| A study on the clinical efficacy and safety of drug-eluting bead transarterial chemoembolization combined with systemic antitumor regimen in treatment of unresectable primary hepatic carcinoma |
|
LIANG Guo-dong, PENG Yong, CONG Peng
|
|
Department of Hepatobiliary, Pancreatic and Splenic Surgery, Nanchong Central Hospital(the Second Clinical Medical College of North Sichuan Medical College), Sichuan 637000, China
|
| Abstract: |
| ［Abstract］ Objective To study the clinical efficacy and safety of drug-eluting bead transarterial chemoembolization(DEB-TACE) combined with systemic antitumor regimen in treatment of unresectable primary hepatic carcinoma(PHC). Methods The clinical data of 99 patients with unresectable PHC who received DEB-TACE treatment in Nanchong Central Hospital from January 2021 to December 2022 were retrospectively analyzed. According to different treatments of combined systemic anti-tumor regimen, the patients were divided into control group(receiving simple DEB-TACE treatment, 44 cases), combined group A(receiving DEB-TACE combined with targeted therapy, 24 cases), and combined group B(receiving DEB-TACE combined with immunotherapy, 16 cases) and combined group C(receiving DEB-TACE combined with immunotherapy plus targeted therapy, 15 cases). The clinical efficacy, survival prognosis and adverse reactions were compared among the four groups. Results The objective response rate(ORR) and disease control rate(DCR) in the combined group A, the combined group B and the combined group C were higher than those in the control group, and the overall survival(OS) time and the progression-free survival(PFS) time in the combined group A, the combined group B and the combined group C were longer than those in the control group, and the differences were statistically significant(P<0.05). There were no significant differences in ORR, DCR, OS time and PFS time among the combined group A, the combined group B and the combined group C(P>0.05). Compared with the control group, the combined group A, the combined group B and the combined group C all showed the characteristic adverse reactions related to the treatment drugs. After symptomatic treatments, the symptoms related to the adverse reactions were alleviated or disappeared, and all the adverse reactions were not above grade Ⅲ. Conclusion DEB-TACE combined with systemic anti-tumor regimen has good clinical efficacy and safety in the treatment of moderate and advanced PHC. |
| Key words: Primary hepatic carcinoma(PHC) Drug-eluting bead transarterial chemoembolization(DEB-TACE) Immunotherapy Targeted therapy |
